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The importance of convective transport. can perform both low- and high-flux dialysis. It is a wide-
Background. Despite technological advances in dialysis spread opinion that convective treatments (like high-
equipment and modalities, survival, morbidity, and quality of flux hemodialysis, hemodiafiltration, and hemofiltration)life of hemodialysis patients are still severely affected by acute
give a clinical advantage versus standard dialysis, whenintradialytic and long-term complications, possibly related to
considering the physiological outcomes. The crucialthe treatment itself. Convective treatments, such as high-flux
hemodialysis, hemodiafiltration, and hemofiltration are increas- point is to demonstrate the superiority of these dialysis
ingly suggested as further improvements over standard diffu- techniques on major outcomes: morbidity, mortality, and
sive hemodialysis. The membranes used for these techniques quality of life.are high-flux semisynthetic and synthetic membranes. Charac-
The main feature of convective treatments is the use ofteristics of these membranes are high permeability, which
high-flux membranes, characterized by high permeabilityallows convective removal of water and electrolytes and higher
clearance of middle and large molecular weight solutes, and for water, low and middle molecular weight solutes (par-
high biocompatibility, which minimizes the “inflammatory re- ticularly in the range of 1,000 to 12,000 Daltons), and
sponse” secondary to interactions between blood and the arti-
high “biocompatibility”. Consequently, in order to eval-ficial material of the hemodialysis system.
uate the potential benefits of convective treatments, weMethods. With the specific aim of verifying the superiority
of convective treatments in reducing morbidity and mortality, should consider not only differences in solute clearances
we performed a review of the published literature. but also differences in biocompatibility. During conven-
Results. Some epidemiological studies suggest that convec- tional hemodialysis with “bioincompatible” membranes
tive treatments reduce morbidity and mortality among dialysis
several cellular mechanisms and biological systems, in-patients. However, the results of the published prospective ran-
cluding complement and the coagulation cascade, aredomized controlled trials are conflicting. Moreover, since con-
vective treatments are usually performed with synthetic bio- activated. This reaction, secondary to interactions be-
compatible membranes, it is hard to separate the effect of tween the blood and the “foreign” artificial material of
convection from the effect of biocompatibility. the hemodialysis system, can be defined as an “inflam-Conclusions. To finally assess the effect of high-flux mem-
matory response”. From the clinical point of view, chronicbranes on morbidity and mortality, the results of two random-
inflammation, evidenced by increased levels of variousized, controlled clinical trials (HEMO study and MPO study)
specifically designed with this aim are needed. acute phase reactants such as C-reactive protein, is a com-
mon feature among dialysis patients. Furthermore, a
strong relation between malnutrition, chronic inflamma-
Survival, morbidity, and quality of life of patients un- tion, and atherosclerosis (MIA syndrome) has been doc-
dergoing hemodialytic treatment are still severely af- umented in this population [1, 2]. Convection through
fected by acute and long-term complications, possibly re- low-flux membranes is low and solute transport is medi-
lated to the treatment itself. Therefore, it is of paramount ated by diffusion. For high-flux membranes convection
importance to improve the general medical care of dial- represents an important transport mechanism, additional
ysis patients and above all the quality of the dialysis to diffusion. For solutes with low molecular weight such
treatment itself. The major technological improvements as urea there is very little performance difference be-
in the dialysis technique are single automatic monitors tween low-flux and a high-flux membranes. On the con-
of dialysis that allow a personalization of the treatment, trary, convection plays a major role in the transport of
dialysis machines with control of utrafiltration, and bicar- solutes with higher molecular weight, like vitamin B12
bonate dialysis. The major progress in dialysis mem- and 2-microglobulin. This could have important impli-
branes are the so-called “biocompatible membranes” that cations for the therapeutic use of high-flux dialyzers.
However, since convective treatments are usually per-
formed with synthetic biocompatible membranes, it isKey words: high-flux hemodialysis, inflammatory response, biocompat-
ibility, dialysis membranes. hard to separate the effect of convection from the effect
of biocompatibility. Convective treatments should re- 2002 by the International Society of Nephrology
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duce the acute and long-term hemodialysis-related com- tein anabolism, or a combination of both is still a matter
of discussion. A role of membrane material as a wholeplications. Among acute complications, cardiovascular
instability is the most frequent and important. Long term (biocompatibility and/or convection) on protein mal-
nutrition has been suggested by Gutierrez et al [7].complications comprise high mortality rate, malnutrition,
dialysis-related amyloidosis, anemia, accelerated athero- However, it must be underlined that Gutierrez findings
on healthy volunteers were not confirmed in uremic pa-sclerosis, and alterations of immune-defense.
tients (abstract; Lim et al, J Am Soc Nephrol 1:366, 1990).
It has been suggested that biocompatible high-flux
CARDIOVASCULAR STABILITY membranes can positively affect the relationship be-
In spite of technological advances, such as monitors tween dietary protein intake (measured as PCR) and
with ultrafiltration control and bicarbonate dialysis, car- dialysis dose (expressed as Kt/V) [9], i.e., that hemodialy-
diovascular instability during the hemodialysis session sis with a biocompatible high-flux membrane results in
is still an important clinical problem affecting a large higher protein intake at every level of Kt/V. However,
percentage of hemodialysis patients. Although its patho- it must be noticed that these studies present major meth-
genesis is multifactorial, a role of membrane material odological drawbacks.
and convection has been suggested. Locatelli et al [4] did not demonstrate an influence of
Chanard et al [3] reported that the incidence of hypo- dialysis membrane or convection on any of the variables
tension, vomiting, cramps, and headaches was lower in related to the nutritional status (body weight, serum
patients dialyzed with high-flux membranes (AN69) albumin, serum transferrin, subscapular skinfold, triceps
compared to those in the control group (cellulose mem- skinfold, mid-arm circumference, plasma cholesterol, or
brane). However, there was a lack of randomization and triglycerides). Similarly, a correlation between Kt/V and
patients in the control group did not use machines with protein catabolic rate was not found. One possible reason
automatically controlled ultrafiltration. for this lack of correlation could be the high levels of
In a prospective randomized multicentric trial, Lo- Kt/V reached in this study. Given that the relationship
catelli at al [4] compared treatments which differed both between PCR and Kt/V is curvilinear, the study partici-
in terms of biocompatibility and permeability of mem- pants probably fall into the plateau region, where the
branes. During the 24 months follow-up, no significant correlation between efficiency and nutritional status is
difference in treatment tolerance and cardiovascular lost. Therefore, in order to provide adequate statistical
stability was demonstrated between the four treatment power, further trials, involving sicker patients with high
groups. As stressed in the paper, it is likely that signifi- prevalence of malnutrition, should be designed.
cant differences in cardiovascular stability were not dem-
onstrated because the incidence of intradialytic hypoten-
ANEMIAsion in the population as a whole was much lower than
Anemia in hemodialysis patients is a complex syn-expected. In two prospective non-randomized studies
drome and many factors other than absolute or relative[5, 6] Altieri et al showed (although with some method-
erythropoietin deficiency may contribute in its pathogen-ological drawbacks) a stabilizing haemodinamic effect of
esis. Among these, bone marrow suppression, probablyon-line predilution hemofiltration compared to ultrapure
induced by the retention of toxic metabolites, may behigh-flux dialysis.
present. Microbiological and pyrogenic contaminationTaken together, these results do not support the hy-
of dialysate and secondary enhanced production of cyto-pothesis that convection and/or membrane biocompati-
kines also play a role in causing or aggravating anemia.bility decrease acute intradialytic clinical symptoms, at
Kobayashi et al [10] reported the positive clinical resultsleast in these study populations.
obtained in eight hemodialysis patients treated with a
large-pore membrane (BK-F polymethylmethacrylate).
NUTRITIONAL ASPECTS This study presented several important limitations: lack
of randomization, small sample size, and absence of aMalnutrition is a common feature among dialysis pa-
tients and is commonly associated with decreased body control group. Similarly, Villaverde et al [11] demonstrated
that the switch from cellulosic to high-flux polysulphoneweight, depleted energy stores (fat tissue), and loss of so-
matic protein (low muscle mass). It has been stated that membrane, in the absence of changes in the dialysis dose,
improved the response to rh-EPO by about 14% in 31low plasma levels of serum albumin, transferrin, prealbu-
min, and other visceral proteins are clinical expressions hemodialysis patients. However, a number of drawbacks
do not allow to draw definitive conclusions from thisof malnutrition. Furthermore, a strong association be-
tween low serum albumin and increased morbidity and study either. Similar considerations apply to the study
of Kawano et al [12], who reported their experience onmortality has been established. If protein malnutrition is
secondary to increased protein catabolism, decreased pro- 10 hemodialysis patients treated with a high-flux dialyzer
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(BK-F). In order to test the same hypothesis with a groups, it is possible to postulate that the main factor
better designed study, Locatelli et al [13] performed a accounting for the effect of on-line HDF on anemia
multicentric, controlled, and randomized trial. To verify correction may be, in addition to the increased dialysis
whether hemodialysis with high-flux membrane (BK-F dose, a reduced inflammatory stimulus from the dialy-
polymethylmethacrylate) improves anemia in compari- sate. Wizemann et al [16] found a significant decrease
son with conventional hemodialysis with cellulose mem- in CRP during HDF in contrast to low-flux dialysis. How-
brane, 84 patients were studied. An increase in hemoglo- ever, as reported above, this acute effect of on-line HDF
bin levels was observed in the population as a whole, on CRP needs further elucidation. Confirming the im-
but this trend was not significantly different between the portance of dialysate sterility on anemia correction, Sit-
conventional and experimental group. In the experimen- ter et al [17] found a significant and sustained reduction
tal group, the tendency of hemoglobin levels to increase of rh-EPO dose in patients switched from conventional
was present at each month during the follow up, possibly bicarbonate hemodialysis with potentially microbiologi-
indicating an insufficient length of the observation pe- cally contaminated dialysate to a similar treatment mod-
riod. It has recently been suggested that on-line treat- ality using on-line-produced ultrapure dialysate. The
ments may have a stronger effect on anemia compared switch also resulted in a lower bacterial contamination,
to conventional treatments or standard HDF techniques. with a significant decrease in CRP and IL-6 levels. In a
These techniques may be more effective in achieving multivariate analysis, IL-6 levels were shown to be
higher hematocrit levels by means of two mechanisms: strongly predictive of rh-EPO dose in both groups (treat-
higher removal of small, medium, and large molecules ment with conventional or ultrapure dialysate). Alto-
and reduced microbiological and pyrogenic contamina- gether, the possibility that at least on-line HDF/HF may
tion of the dialysate. Maduell et al [14] followed for achieve a better control of anemia is intriguing. How-
1 year 37 patients after they had been switched from ever, results are conflicting, mainly because of differ-
conventional HDF to on-line HDF. A significant in- ences in treatment modalities in control groups, small
crease in hemoglobin and hematocrit were observed dur- number of enrolled patients, and because anemia was
ing the on-line HDF period. This allowed a significant
not the primary outcome in any of the studies on on-
decrease in the rh-EPO doses. It should be noted that
line HDF/HF. Furthermore, on-line HDF often achievedthe patients also experienced an improvement in dialysis
higher dialysis dose than control treatments, furtherdose (with a 15% increase in Kt/V) during the on-line
complicating the interpretation of these observations.HDF period. Grillo et al (abstract; Nephrol Dial Trans-
The results of prospective randomized trials specificallyplant 14:207, 1999) studied 31 patients, who had been
designed to test this hypothesis are awaited.on on-line HDF for at least 9 months. They found a
significant increase in hemoglobin levels and a conse-
quent reduction in rh-EPO consumption (not statistically DIALYSIS-RELATED AMYLOIDOSIS
significant). Kt/V remained constant during the course
In a retrospective analysis, Van Ypersele de Strihou
of the study. Other studies could not confirm these obser-
et al [18] demonstrated lower incidence of cystic bonevations. Ward et al [15] prospectively compared two con-
lesions in patients treated with a synthetic membranevective techniques (on-line HDF and high-flux hemodi-
(AN69) compared to those treated with a cuprophanealysis) in 44 patients, who were followed for one year.
membrane.Although the control of anemia was not a primary out-
Kuchle et al [19] conducted a trial on 20 patients pre-come, there was no significant change in hematocrit or
viously treated with low-flux cuprophane membraneshemoglobin over the course of the study. The average
who were randomized to continue the same hemodialysisweekly dose of rh-EPO slightly increased, but this modi-
regimen or to receive high-flux polysulfone membranesfication was independent of the dialysis technique. Wize-
dialysis. After 6 years of follow up, no clinical signs ofman et al [16] also failed to confirm the possible effect
dialysis-associated amyloidosis were found in any of theof convection (on-line HDF) on the correction of ane-
10 patients dialyzed with high-flux polysulfone mem-mia. In this prospective controlled study, 44 patients
branes. On the contrary, eight out of 10 patients dialyzedwere randomized to undergo either low-flux hemodialy-
with cuprophane membranes presented carpal tunnelsis or on-line HDF. To eliminate confounding factors,
syndrome and/or osteoarticular lesions. Using data fromlow-molecular efficacy (Kt/V  1.8), treatment duration
the Lombardy Registry, Locatelli et al [20] performed a(4.5 h), and membrane (polysulphone) were matched. It
historical prospective study of 6,440 patients who hadhas to be noted that the two groups differed not only
started renal replacement therapy between 1983 andfor convection but also for levels of biocompatibility.
1995. These authors found that the relative risk for carpalAfter 24 months of follow-up, hematocrit levels and rh-
tunnel syndrome surgery (evaluated as a parameter ofEPO dose did not differ between the two groups. Given
that the same ultrapure dialysate was used in both morbidity) was 44% lower for patients treated with hem-
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Fig. 1. Impact of dialysis membrane and flux
on patient mortality.
odiafiltration or haemofiltration (RR  0.56; 95% c.i. polysulfone and 463 patients treated for at least 3 months
0.34–0.92; P  0.02). and up to 5 years with high-flux polysulfone. The patients
In a study by Koda et al [21], 248 patients were either treated with high-flux polysulfone experienced lower
switched from conventional to high-flux membrane or mortality (21 vs. 36 per 1000 years; P  0.01) and pre-
treated with a high-flux membrane only. Again, the rela- sented higher survival at 5 years (90 vs. 60%; P 0.029).
tive risk of CTS resulted significantly reduced (0.503; In a Cox proportional hazards model, high-flux dialysis
P  0.05). was associated with a 70% reduction in death-risk when
On the other hand, in a retrospective analysis on 122 compared to low-flux.
patients Bonomini et al [22] did not demonstrate any In a historical prospective study of 2410 patients from
difference in 2-microglobulin related morbidity be- the United States Renal Data System (USRDS), Hakim
tween cellulose and synthetic membranes. et al [26] applied a Cox proportional hazards model to
Using data from the Japanese dialysis patient registry, estimate the relative risk of mortality. After adjusting for
Nakai et al [23] performed a retrospective study on 1196 dialysis dose, geographic distribution, and comorbidity,
patients who were undergoing renal replacement therapy the relative risk of mortality in patients dialyzed with
at the end of 1998 and who developed dialysis-related modified cellulose or synthetic membranes was 20% lower
amyloidosis during 1999. The risk of developing dialysis- compared to patients treated with unsubstituted cellu-
related amyloidosis (being the risk for conventional he- lose membranes. Analyzing a sample from the USRDS,
modialysis equal to 1) was found to be progressively Bloembergen et al [27] demonstrated that, after ad-
lower for high-flux hemodialysis (0.489), off-line hemodi- justing for dialysis dose and co-morbidity, all-cause mor-
afiltration (0.117), and on-line hemodiafiltration (0.013). tality (RR 0.82; P  0.002), and mortality due to infec-
tions (RR 0.69; P  0.03) were significantly lower in
patients dialyzed with synthetic or substituted cellulosicMorbidity and mortality
membranes compared to patients dialyzed with unmodi-The most relevant findings on the impact of dialysis
fied cellulosic membranes. Remarkably, no differencesmembrane and flux on patients mortality are summarized
in mortality due to cardiovascular causes were observed.in Figure 1. Chanard et al [3] reported that the use of a
Koda et al [21] reported that the use of high-flux mem-high-flux biocompatible membrane (PAN) was related
branes was associated with better survival of dialysisto positive effects on hospitalization index and number
patients (relative risk for mortality  0.613; P  0.05).of hospitalization days compared to cuprophan mem-
A recent retrospective study performed by Leypoldt etbranes. Mortality did not differ between the two groups.
al [28] on a large data subset from the USRDS showedHornberger et al [24] performed a retrospective study
a 5% reduction in mortality (after correction for casecomparing 146 patients on standard hemodialysis to 107
mix, co-morbidity factors, and urea Kt/V) of the patientspatients on high flux hemodialysis. The relative risk of
treated with membranes that increased the removal ofmortality on high flux hemodialysis was 0.24 (95% con-
vitamin B12 by 10%. Given that the vitamin B12 (mole-fidence limits: 0.12–0.49). In a retrospective analysis of
cular weight: 1355 Daltons) is considered a middle mole-715 patients, Woods and Nandakumar [25] identified two
groups: 252 patients treated exclusively with low-flux cules marker, the authors concluded that the removal of
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3. Chanard J, Brunois IP, Melin JP, et al: Long-term results ofmiddle (and small) molecules is independently related
dialysis therapy with a highly permeable membrane. Artif Organs
to the risk of mortality in dialysis patients. 6:261–266, 1982
In 6,440 patients treated in Lombardy between 1983 4. Locatelli F, Mastrangelo F, Redaelli B, et al: Effects of dif-
ferent membranes and dialysis technologies on patient treat-and 1995, Locatelli et al [20] found that the relative
ment tolerance and nutritional parameters. Kidney Int 50:1293–risk for mortality was not significantly lower when using 1302, 1996
convective treatments (RR  0.90). 5. Altieri P, Sorba GB, Bolasco PG, et al: On-line predilution
hemofiltration versus ultrapure high-flux hemodialysis: A multicen-Port et al [29] performed a very large-sized retrospec-
ter prospective study in 23 patients. Blood Purif 15:169–181, 1997tive study, evaluating 12,791 patients on hemodialysis 6. Altieri P, Sorba G, Bolasco PG, et al: Predilution haemofiltra-
from 1994 through 1995 with 1 to 2 years of follow-up. tion – the second sardinian multicentre study: comparisons between
haemofiltration and haemodialysis during identical Kt/V and ses-These authors reported that the relative risk for mor-
sion times in a long-term cross-over study. Nephrol Dial Transplanttality was lower for synthetic membranes compared to 16:1207–1213, 2001
other kinds of membranes (RR  0.82, 95%, CI 0.72 7. Gutierrez A, Bergstrom J, Alvestrand A: Protein catabolism
in sham haemodialysis: the effect of different membranes. Clinto 0.93, P  0.002). Among synthetic membranes, the
Nephrol 38:20–29, 1992relative risk for mortality was higher with low-flux than
8. Deleted in proof.
with high-flux membranes (RR  1.24, 95%, CI 1.02 to 9. Lindsay RM, Spanner E, Heidenheim AP, et al: A multicentre
study of short hour dialysis using AN69—preliminary results.1.52, P  0.04). These results suggest that both biocom-
ASAIO Trans 37:465–467, 1991patibility and flux membrane characteristics may play a
10. Kobayashi H, Ono T, Yamamoto N, et al: Removal of high molecu-
role in improving survival of hemodialysis patients. lar weight substances with large pore size membrane (BK-F). Kid-
ney Dial 34(Suppl):S154–S157, 1993
11. Villaverde M, Pe´rez-Garcia R, Verde E, et al: La polisulfona
de alta permeabilidad majora la respuesta de la anemia a la eritro-CONCLUSIONS
poyetina en hemodialisis. Nefrologia 19:161–167, 1999Several epidemiological studies suggest that convec- 12. Kawano Y, Takaue Y, Kuroda Y, et al: Effect on alleviation of
tive treatments seem to reduce morbidity and mortality renal anemia by hemodialysis using the high-flux dialyzer (BK-F).
Kidney Dialy 200–203, 1994among dialysis patients. The results of the published
13. Locatelli F, Andrulli S, Pecchini F, et al: Effect of high-fluxprospective randomized controlled trials are conflicting. dialysis on the anaemia of haemodialysis patients. Nephrol Dial
It is likely that the concept of dialysis adequacy has to Transplant 15:1399–1409, 2000
14. Maduell F, del Pozo C, Garcia H, et al: Change from conven-be widened to include, besides urea kinetics, medium
tional haemodiafiltration to on-line haemodiafiltration. Nephroland high molecules removal as well as biocompatibility.
Dial Transplant 14:1202–1207, 1999
To assess the effect of dialysis membranes on mortal- 15. Ward RA, Schmidt B, Hullin J, et al: A comparison of on-line
hemodiafiltration and high flux hemodialysis: a prospective clinicality, two randomized, controlled clinical trials have been
study. J Am Soc Nephrol 11:2344–2350, 2000designed: the Hemodialysis (HEMO) study [30] and the
16. Wizemann V, Lotz C, Techert F, Uthoff S: On-line haemodiafil-
Membrane Permeability and ESRD Patient Outcome tration versus low-flux haemodialysis. A prospective randomised
study. Nephrol Dial Transplant 15(Suppl 1):S43–S48, 2000(MPO) study [31]. The HEMO study began in the United
17. Sitter T, Bergner A, Schiffl H: Dialysate related cytokine induc-States in 1995 and should be concluded by the end of
tion and response to recombinant human erythropoietin in haemo-
2001. Its 2  2 factorial design considers patient out- dialysis patients. Nephrol Dial Transplant 15:1207–1211, 2000
18. Van Ypersele de Strihou C, Jadoul M, Malghem J, et al: Effectcomes in relation to two different dialysis doses (an equil-
of dialysis membrane and patient’s age on signs of dialysis relatedibrated Kt/V of 1.05 or 1.45) and two different levels of
amyloidosis. Kidney Int 39:1012–1019, 1991
convection (low- or high-permeability dialysis mem- 19. Kuchle C, Fricke H, Held E, Schiffl H: High-flux hemodialysis
branes). The MPO study, which started in Europe in postpones clinical manifestation of dialysis-related amyloidosis.
Am J Nephrol 16:484–488, 1996December 1998 and should be concluded by the end
20. Locatelli F, Marcelli D, Conte F, et al: Comparison of mortalityof 2005, is specifically designed to assess the effect of in ESRD patients on convective and diffusive extracorporeal treat-
membrane permeability. Unlike the HEMO study, the ments. Kidney Int 155:286–293, 1999
21. Koda Y, Nishi S, Miyazaki S, et al: Switch from conventionalMPO study only enrolled incident patients. Given the
to high-flux membrane reduces the risk of carpal tunnel syn-importance of this issue, the results of these two large drome and mortality of hemodialysis patients. Kidney Int 52:1096–
trials are awaited with much interest. 1101, 1997
22. Bonomini V, Coli L, Feliciangeli G, et al: Long-term comparative
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